Drug Approval | June 26, 2024
USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Subscribe To Our Newsletter & Stay Updated
